Zhihua Yao
YOU?
Author Swipe
View article: Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study
Liposomal mitoxantrone versus chidamide in relapsed/refractory peripheral T-cell lymphoma: Final analysis from the multicenter, prospective randomized phase 3 study Open
Background Outcomes for patients with relapsed/refractory (R/R) peripheral T-cell lymphomas (R/R-PTCLs) are poor. Single agent overall response rates (ORRs) for R/R-PTCLs generally fall within the 20-35% range, with a median progression-fr…
View article: Fat-rich diet reprograms intrapulmonary neutrophils to boost tissue-specific antitumor immunity
Fat-rich diet reprograms intrapulmonary neutrophils to boost tissue-specific antitumor immunity Open
Neutrophils adapt to tissue-specific signals and exert innate defense functions against infections and malignancies. Fat-rich diet (FRD), such as high-fat diet (HFD) and ketogenic diet (KD), has complex impacts on immunity. However, whethe…
View article: Designing Single-Arm Clinical Trials: Principles, Applications, and Methodological Considerations
Designing Single-Arm Clinical Trials: Principles, Applications, and Methodological Considerations Open
Single-arm trials (SATs) are clinical studies without a parallel control group, serving as a vital alternative to randomized controlled trials (RCTs) in scenarios where traditional trial designs are impractical. These trials are particular…
View article: A modified elastoplastic damage structural constitutive model of unsaturated Q3 undisturbed loess
A modified elastoplastic damage structural constitutive model of unsaturated Q3 undisturbed loess Open
The weakening of loess structure under hydro-mechanical effect is an important reason for collapsible deformation of loess. Therefore, when establishing the constitutive model of unsaturated loess, it is necessary to consider the influence…
View article: UWB Sensors Optimization Deployment for Narrow and Long Space Environments
UWB Sensors Optimization Deployment for Narrow and Long Space Environments Open
In this paper, a detailed study on Ultra-wideband (UWB) sensor deployment was carried out to satisfy requirements of achieving higher positioning accuracy for the narrow and long underground roadway. We derived the dilution of precision (D…
View article: Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma
Phase Ib/IIa Study of Amulirafusp Alfa (IMM0306) in Combination with Lenalidomide in Patients with Relapsed or Refractory CD20-Positive B-Cell Non-Hodgkin's Lymphoma Open
Introduction: Amulirafusp alfa (IMM0306) is a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα added on the N-terminus of both heavy chains. It exerts potent cancer killing efficacy by activating both macrop…
View article: [A consistency comparison between next-generation sequencing and the FISH method for gene rearrangement detection in B-cell lymphomas].
[A consistency comparison between next-generation sequencing and the FISH method for gene rearrangement detection in B-cell lymphomas]. Open
Objective: To compare the consistency of lymphoma multigene detection panels based on next-generation sequencing (NGS) with FISH detection of B-cell lymphoma gene rearrangement. Methods: From January 2019 to May 2023, fusion genes detected…
View article: Severe inflammation in C57/BL6 mice leads to prolonged cognitive impairment by initiating the IL-1β/TRPM2 pathway
Severe inflammation in C57/BL6 mice leads to prolonged cognitive impairment by initiating the IL-1β/TRPM2 pathway Open
A continuous increase in IL-1β levels within the hippocampus can lead to cognitive impairment by enhancing TRPM2 levels caused by severe inflammation.
View article: Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma
Preliminary Results of a Phase Ⅱ Study of Lenalidomide Combined with Immunochemotherapy in Patients with Primary Central Nervous System Lymphoma Open
Conclusion Introduction：PCNSL is a diffuse large B cell lymphoma (DLBCL) occurring exclusively in the brain, spinal cord, cranial nerves, leptomeninges and/or eyes. Pathophysiology is incompletely understood, although a central role seems …
View article: Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up
Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up Open
Introduction Patients with relapsed or refractory (r/r) DLBCL had poor prognosis when ineligible to autologous hematopoietic stem cell transplantation (auto-HSCT). Polatuzumab vedotin (Pola) has demonstrated significant efficacy and accept…
View article: Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study
Selective PI3Kδ Inhibitor Parsaclisib Combined with HDAC Inhibitor Chidamide in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma: Preliminary Results of a Phase Ib/Ⅱ Study Open
Background: Peripheral T-cell lymphoma (PTCL) is a highly heterogenous non-Hodgkin lymphoma with poor survival. Pts with relapsed/refractory PTCL (r/r PTCL) have extremely poor prognosis and limited treatment options. Conventional salvage …
View article: A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy
A retrospective study of autologous hematopoietic stem cell transplantation for peripheral T-cell lymphoma: pre-transplant patients with partial remission benefit from post-transplant maintenance therapy Open
Background Whether autologous hematopoietic stem cell transplantation (ASCT) improves the survival of patients with peripheral T-cell lymphoma (PTCL) remains controversial. Some studies have demonstrated that the efficacy of ASCT is superi…
View article: Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review
Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review Open
Most episodes of HBV-R are preventable, and most cases with HBV-R are manageable. We recommend that novel anticancer drugs should not be intentionally avoided when treating cancer patients with HBV infection.
View article: Figure S3 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S3 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S3 shows the survival curve of patients treated by CHOP regimen.There was survival indifference between patients with distinct CACNA1C expression in the setting of CHOP treatment (p>0.05).
View article: Figure S4 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S4 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S4 shows CACNA1C and CD20 expression and their association with rituximab response in DLBCL cell lines.(A and B) CACNA1C and CD20 mRNA expression were different among OCI-ly3, OCI-ly7, and OCI-ly8 cell lines (p<0.05). (C-E) CACNA1C …
View article: Figure S2 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S2 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S2 shows probe sets for CACNA1c on HG-U133plus2 platform.
View article: Data from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Data from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Purpose:One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the pot…
View article: Figure S5 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S5 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S5 shows the influence of L-type calcium channel modulators on rituximab-mediated calcium influx and CD20 expression.(A) Nimodipine weakened rituximab-induced increase of intracellular calcium ions, whereas Bay K8644 enhanced it in …
View article: Figure S1 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S1 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S1 shows the design of regulating the expression of miRNA-363.(A) The construction of FUA based miRNA-363 lentiviral vector; (B) The scheme of miRNA-363 knockout using CRISPR/Cas9 system.
View article: Figure S2 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S2 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S2 shows probe sets for CACNA1c on HG-U133plus2 platform.
View article: Figure S6 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S6 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S6 shows the knockout of CACNA1C using CRISPR/Cas9 system.The expression of CACNA1C was knockout using its sgRNA1 and 5 CRISPR/Cas9 system, which resulted in the obvious apoptosis of these edited cells.
View article: Figure S4 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S4 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S4 shows CACNA1C and CD20 expression and their association with rituximab response in DLBCL cell lines.(A and B) CACNA1C and CD20 mRNA expression were different among OCI-ly3, OCI-ly7, and OCI-ly8 cell lines (p<0.05). (C-E) CACNA1C …
View article: Data from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Data from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Purpose:One third of patients with diffuse large B-cell lymphoma (DLBCL) succumb to the disease partly due to rituximab resistance. Rituximab-induced calcium flux is an important inducer of apoptotic cell death, and we investigated the pot…
View article: Figure S3 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S3 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S3 shows the survival curve of patients treated by CHOP regimen.There was survival indifference between patients with distinct CACNA1C expression in the setting of CHOP treatment (p>0.05).
View article: Figure S1 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S1 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S1 shows the design of regulating the expression of miRNA-363.(A) The construction of FUA based miRNA-363 lentiviral vector; (B) The scheme of miRNA-363 knockout using CRISPR/Cas9 system.
View article: Figure S5 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S5 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S5 shows the influence of L-type calcium channel modulators on rituximab-mediated calcium influx and CD20 expression.(A) Nimodipine weakened rituximab-induced increase of intracellular calcium ions, whereas Bay K8644 enhanced it in …
View article: Figure S6 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma
Figure S6 from L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma Open
Figure S6 shows the knockout of CACNA1C using CRISPR/Cas9 system.The expression of CACNA1C was knockout using its sgRNA1 and 5 CRISPR/Cas9 system, which resulted in the obvious apoptosis of these edited cells.
View article: Treatment of extranodal NK/T-cell lymphoma: From past to future
Treatment of extranodal NK/T-cell lymphoma: From past to future Open
Extranodal NK/T-cell lymphoma (ENKTCL) is the most common subtype of T/NK-cell lymphoma in Asia and Latin America, but very rare in North American and Europe. Patient survival has improved significantly over the past two decades. However, …
View article: A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma
A retrospective cohort study of polatuzumab vedotin combined with immunochemotherapy in Chinese patients with relapse/refractory diffuse large B cell lymphoma Open
These preliminary data suggested that the pola-BR regimen has promising efficacy and tolerable safety in Chinese transplantation ineligible R/R DLBCL patients. Hence, pola-BR may be an optional regimen. Considering the limited sample size …